Log In
Print
BCIQ
Print
Print this Print this
 

MP4CO

  Manage Alerts
Collapse Summary General Information
Company Sangart Inc.
DescriptionPegylated carboxyhemaglobin
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSickle cell disease
Indication DetailsTreat acute painful sickling crises in patients with sickle cell disease; Treat sickle cell disease
Regulatory Designation

U.S. - Orphan Drug (Treat acute painful sickling crises in patients with sickle cell disease);
EU - Orphan Drug (Treat acute painful sickling crises in patients with sickle cell disease)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today